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Abstract
Purpose: The DNA methylation inhibitor 5-aza-29-deoxycytidine (DAC) is approved for the treatment of myelodysplastic
syndromes (MDS), but resistance to DAC develops during treatment and mechanisms of resistance remain unknown.
Therefore, we investigated mechanisms of primary and secondary resistance to DAC in MDS.
Patients and Methods: We performed Quantitative Real-Time PCR to examine expression of genes related to DAC
metabolism prior to therapy in 32 responders and non-responders with MDS as well as 14 patients who achieved a
complete remission and subsequently relapsed while on therapy (secondary resistance). We then performed quantitative
methylation analyses by bisulfite pyrosequencing of 10 genes as well as Methylated CpG Island Amplification Microarray
(MCAM) analysis of global methylation in secondary resistance.
Results: Most genes showed no differences by response, but the CDA/DCK ratio was 3 fold higher in non-responders than
responders (P,.05), suggesting that this could be a mechanism of primary resistance. There were no significant differences
at relapse in DAC metabolism genes, and no DCK mutations were detected. Global methylation measured by the LINE1
assay was lower at relapse than at diagnosis (P,.05). On average, the methylation of 10 genes was lower at relapse (16.1%)
compared to diagnosis (18.1%) (P,.05).MCAM analysis showed decreased methylation of an average of 4.5% (range 0.6%–
9.7%) of the genes at relapse. By contrast, new cytogenetic changes were found in 20% of patients.
Conclusion: Pharmacological mechanisms are involved in primary resistance to DAC, whereas hypomethylation does not
prevent a relapse for patients with DAC treatment.
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Introduction
The myelodysplastic syndrome (MDS) encompasses a diverse
group of clonal hematopoietic disorders united by ineffective
production of blood cells and varying risks of transformation to acute
myelogenous leukemia (AML). MDS is typically a disease of older
adults [1]. Epigenetic deregulation plays an important role in the
pathogenesis of MDS. Hypermethylation of CpG islands in the
promoter of tumor-associated genesand theirconsequent silencing are
important in the pathogenesis of MDS [2],[3]. Reversal of aberrant
methylation leads to re-expression of silenced tumor suppressor genes
and appears to be important in the response and prognosis of patients
treated with DAC [4]. The prototypical DNA methyltransferase
inhibitor 5-aza-29-deoxycytidine (decitabine, 5-aza-dC, DAC) and 5-
azacytidine (AZA) have been approved by the Food and Drug
Administration (FDA) as antitumor agents for the treatment of MDS.
Low-dose decitabine has been studied recently in multiple clinical
trials and has been shown to be effective for treatment of MDS [4,5].
In clinical trials, it was found that a number of patients do not
respond to DAC initially (primary resistance) and most patients who
initially respond to DAC treatment, eventually relapse (secondary
resistance) despite continued DAC therapy [4]. Mechanisms of
primary and secondary resistance to existing DNA methylation
inhibitors have not been determined. Most primary mechanisms of
resistance to cytosine analogues (NAs) are based on metabolic
pathways [6,7]. A primary mechanism is an insufficient intracellular
concentration of NA triphosphates, which may result from multiple
factors including insufficient uptake through membrane transport-
ers, deoxycytidine kinase (dCK) deficiency, increased deamination
by cytidine deaminase (CDA), or high dNTP pools.
We previously found that mechanisms of naturally occurring
resistance to DAC in vitro in a panel of cancer cell lines was
primarily due to insufficient intracellular triphosphate, resulting
from DCK mutations or aberrant gene expression [8]. Here we
tested mechanisms of primary and secondary resistance to DAC in
vivo in MDS patients.
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Patients
Adults with a diagnosis of MDS who were referred to MD
Anderson Cancer Center were enrolled in the study after informed
consent was obtained according to institutional guidelines and in
accordance with the Declaration of Helsinki. Patients were
categorized for MDS risk at the initiation of decitabine therapy
and at the time of failure of decitabine according to the IPSS [9]
and to the MDACC risk model [10].Bone marrow and/or
peripheral blood cells were collected from consenting patients
according to institutional guidelines and an IRB approved
protocol. Genomic DNA was isolated using DNA STAT-60
reagent (Iso Tex Diagnostics, Friendswood, TX) according to the
manufacturer’s instructions.
Bisulfite-pyrosequencing for methylation analysis
Bisulfite treatment was performed as reported previously [11],
[12]. Bisulfite-treated DNA (40–80 ng) was amplified with gene-
specific primers in a 2-step polymerase chain reaction (PCR).
Primer sequence for 5 genes and LINE1 analyzed are shown in
Table S1. The second step of PCR was used to label single DNA
strands with biotin using a universal primer tag [13] or gene-
specific primers biotinylated at the 59end. We measured levels of
DNA methylation as the percentage of bisulfite-resistant cytosines
at CpG sites by pyrosequencing with the PSQ HS 96
Pyrosequencing System (Biotage, Charlottesville, VA) and Pyro
Gold CDT Reagents (Biotage) as previously described [13].
Quantitative reverse transcription-PCR
Real-time quantitative reverse transcription-PCR was done with
the ABI 7700 Sequence Detector (Applied Biosystems).We used
commercially available primers sets with minor groove binder
probe for genes and GAPDH as an internal control (Applied
Biosystems). Reactions for quantitative reverse transcription-PCR
were done with the TaqMan universal PCR Master Mix kit
(Applied Biosystems) in 96-well plates. Each sample was measured
in triplicate. PCR was run using the following conditions: an initial
denaturation step of 95uC for 10 min followed by 40 cycles at
95uC for 15 s and 60uC for 1 min. Data were analyzed with ABI
Prism 7000 SDS software (Applied Biosystems).
Sequencing of DCK
We performed RT-PCR on the full coding region of DCK and
amplified a PCR product to directly sequence DCK gene
mutations. The forward primer 59 TCTTTGCCGGACGAGC-
TCTG 9 and reverse primer 59 CAGGCAGCCAAATGGTTC
39, cover the full coding region from exon 1 to exon 7. The length
of this PCR product is 858 bp. PCR was run using the following
conditions: an initial denaturation step of 95uC for 5 min followed
by 40 cycles at 95uC for 15 s, 60uC for 30 s, and 72uC for 60 s.
Methylated CpG island microarray (MCAM)
We used DNA from the bone marrow samples of 4 patients with
MDS obtained at the time of initial diagnosis and at the time of
first relapse. Methylated CpG island amplification was performed
as described [14]. Amplicons from patients with MDS after relapse
were labeled with the Cy5 dye and cohybridized against amplicons
from patients at diagnosis labeled with the Cy3 dye on Agilent
Technologies 4644 K custom DNA microarrays (Agilent, Santa
Clara, CA) as described previously [15]. Dye swaps were
preformed for comparison. This method allows parallel analysis
of 42222 probes corresponding to 9008 autosomal genes. The
probes on the array were selected to recognize SmaI/XmaI
fragments, mostly around gene transcription start sites. We used
normalized signal intensity based on Agilent software to perform
microarray hybridization analysis as previously described [15]. We
used probes located outside of SmaI/XmaI fragments (length up to
10 kb) for normalization and background calculation. The signal
intensity for the probes within the SmaI/XmaI fragments was
adjusted for background and analyzed for the ratio between Cy3
and Cy5 signals. The ratios of hybridization intensities were
adjusted by using Lowess normalization.
Statistical Analysis
Statistical differences between different patient groups were
analyzed by Mann-Whitney nonparametric t-test. Statistical
differences between same patient groups were analyzed by paired
t test. 2-sided P values,0.05 were considered statistically
significant. All calculations were done using GraphPad Prism 4.0
(GraphPad Software Inc.). The stata 10 was used for univariate
and multivariate analysis of the correlation of biological features
with drug response.
Results
Patients studied
We examined patients with primary resistance (never respond-
ed) and secondary resistance (responded then relapsed) to DAC.
For primary resistance, we included 32 patients who were
randomized to receive DAC 20 mg/m
2 intravenously over 1 hour
daily for 5 days. For the secondary resistance study, we included
14 patients from a different clinical trial who were randomized to
receive DAC in 20 mg/m
2 intravenously over 1 hour daily for 5
days. The patients were considered to have not responded only
after having received at least 3 courses of therapy. Patient
characteristics are described in Table 1. There were no statistically
significant difference in disease characteristics between responders
and non-responders in patients with primary resistance, but bone
marrow blast (%) in patients with secondary resistance at the
diagnosis was lower than at relapse (7% vs 16%, P,0.05).
DAC metabolism gene expression in primary resistance
We compared the expression of a group of genes related to the
metabolism of DAC including hENT1, hENT2, hCNT3, DCK,
CDA and 5 9-NT between responders and non-responders.
Individually, none of the genes were significantly different between
responders and non-responders (Figure 1). There was a trend for
DCK expression to be lower in non-responders (P=0.076,
Figure 1). There was also a trend for CDA, which inactivates
DAC, to be higher in non-responders (P=0.10) (Figure 1). We
therefore examined the ratio of CDA/DCK and found that it was
1.260.37 in responders, but significantly increased to 3.460.85 in
non-responders with the primary resistance (P=0.027) (Figure 1).
These results suggest that primary resistance to DAC may be due
to increased deamination and decreased phosphorylation in a
subset of patients with primary resistance.
DAC metabolism gene expression in secondary
resistance
Using quantitative real-time PCR, the mRNA expression levels
of genes related to DAC metabolism including hENT1, hENT2,
hCNT3, DCK, CDA, MDR1 were measured at diagnosis and at
relapse. Detectable amounts of all nine genes were found in all 14
samples. There was no significant difference in mRNA expression
of these genes between diagnosis and relapse. There was also no
significant difference in the CDA/DCK ratio (Figure 2). We next
measured mRNA expression of DNA methyltransferase genes
DAC Resistance in MDS
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difference in gene expression between diagnosis and relapse
(Figure 2). Furthermore, we sequenced the DCK coding region for
mutations in patients after relapse. We obtained 16 patient
samples after relapse, extracted RNA, and synthesized cDNA. We
used the primers that covered the full coding region of DCK. No
mutations were detected in the coding region of all the samples.
Thus, DCK mutations or mRNA expression of DAC metabolism
genes do not explain secondary resistance.
DNA methylation analysis at relapse
We next asked whether patients who relapsed after an initial
response to DAC showed any significant difference in gene
methylation. We studied global methylation of LINE1 and the
following genes: CDKN2B (p15
INK4b), PGRA, PGRB, OLIG2,
NOR1, CDH13, MAPK15, miR-124a-1, and miR-124a-3 by
bisulfite pyrosequencing in 12–20 MDS patient samples. Methyl-
ation of those genes has been described in leukemia. For example,
P15 is inactivated selectively in leukemias and gliomas and seems
to constitute an important tumor suppressor gene loss in these
neoplasms [16]; CDH13 expression by aberrant promoter
methylation occurs at an early stage in CML pathogenesis [17];
Extensive methylation of PGRA and PGRB was also observed in
leukemia samples [18]; miR-124-1 is a tumor suppressor micro-
RNA (miR). Epigenetic deregulation of miR is implicated in
haematological malignancies [19]. Paired t-test analysis comparing
methylation levels at baseline and relapse showed that there was
hypomethylation of LINE1 (P=0.01) at relapse, a trend for
hypomethylation of PGRB (P=0.08) and miR-124a-3 (P=0.08) at
relapse, and no significant differences in other genes (Figure 3A).
On average, methylation density was significantly decreased from
18.1%620.5% at diagnosis to 16.1%618.4% at relapse by
Wilcoxon signed rank test (P=0.02). All changes in DNA
methylation status in individual patients between diagnosis and
relapse are shown in Figure 3B. Considering a 10% difference as
significant, 11/199 (5.5%) measurements showed increased
methylation after relapse, 25/199 (12.5%) showed decreased
methylation, and 164 showed no differences (Figure 3B). Thus,
analysis of these genes suggested that patients had more
hypomethylation after relapse.
Next, we analyzed genome wide methylation by MCAM [14] in
4 patients at diagnosis and relapse. In each case, we cohybridized
DNA from diagnosis and relapse in the same slide. A representative
M-A plot of the data in one patient is shown in Figure 4A. We
calculatedthe frequencyofmethylationchange inSmaIfragmentsin
that patient, and found that 15.5% of SmaI fragments were
hypomethylated while 1.2% were hypermethylated (Figure 4B). A
M-Aplotaveragingofthedatainall4patientsisshowninfigure4C.
On average, 4.7% of SmaI fragments were hypomethylated
compared with 0.4% , which were hypermethylated (Figure 4D).
We next analyzed the data for SmaI sites within 1 kb of
transcription starting sites, and used a more stringent criterion for
hyper/hypomethylation (M value.1.5 or ,21.5) to reduce false
positives. In this analysis of 6832 genes, hypomethylation at
relapse averaged 4.5% (range 0.6%–9.7%), while hypermethyla-
tion averaged 0.9% (range 0.1%–2.0%). Among these genes,
hypermethylation in 2 or more cases was rare (0.33%) and
hypomethylation was seen in 6% of loci in 2 or more cases.
(Figure 4E, 4F). A list of genes modified in 2 or more patients is
shown in Table S2, S3, S4.
Table 1. Patients studied for secondary resistance.
Clinical Characteristic Primary Resistance, Median (Range) Secondary Resistance, Median (Range)
Responders (N=16) Non-responders (N=16) Diagnosis (N=30) Relapse (N=30)
Age, years 70 (56–83) 68 (50–84) 69 (56–81)
Males, n(%) 14 (87) 9 (56) 20 (67)
Overall survival duration, months 18 (8–36)
Time from diagnosis to relapse, months 11 (3–24)
Time from relapse to death, months 4 (2–26)
Bone Marrow Blasts (%) 4 (0–15) 12 (1–70) 7 (0–15) 16 (2–55)*
White Blood Cells, 10
3/mL 13.1 (3.5–61.5) 8.6 (0.1–44.4) 3.8 (0.9–83.5) 2.8 (0.7–145.4)
Hemoglobin, g/dL 11.2 (8.1–14.7) 9.5 (8.3–11.5) 9.7 (6.7–14.1) 9.7 (7.4–13.6)
Platelets, 10
3/mL 100 (8–262) 43 (4–129) 75 (10–392) 43 (5–486)
Karyotype, n (%)
Good 9 (56) 4 (24) 15 (30) 12 (25)
Intermediate 2 (12) 3 (18) 11 (36) 12 (25)
Poor 2 (12) 6 (36) 4 (13) 6 (20)
Unclassified 3 (18) 3 (18) 0 0
IPSS risk category, n (%)
Low 3 (19) 2 (13) 6 (20)
Intermediate-1 4 (25) 2 (13) 9 (30)
Intermediate-2 4 (25) 4 (25) 8 (27)
High 1 (6) 4 (25) 4 (14)
Unclassified 4 (25) 4 (25) 5 (17)
*P,0.05.
doi:10.1371/journal.pone.0023372.t001
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2 or more patients showed enrichment of network functions in
lipid metabolism, small molecule biochemistry, cell cycle, genetic
disorders, cancer, DNA replication, recombination, and repair.
Ingenuity analysis of those genes commonly hypomethylated in 2
or more patients showed enrichment of network functions in lipid
metabolism, small molecule biochemistry, cell cycle, genetic
disorders, cancer, DNA replication, recombination, and repair
(Figure 5A and 5B). For example, ARHGDIA is a Rho GDP-
dissociation inhibitor, Sox5, 12 and 13 regulate transcription.
Figure 1. DAC metabolism gene expression in primary resistance. mRNA expression of genes related to DAC metabolic pathways including
hENT1, hENT2, hCNT3, 59-NT, CDA and DCK were measured by Quantitative Real-Time PCR in 16 responders and 16 non-responders with primary
resistance to DAC. GAPDH was used as an internal control. Statistical analysis of the differences in gene expression was performed by unpaired t tests.
doi:10.1371/journal.pone.0023372.g001
DAC Resistance in MDS
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immune response. MAPK, Stat 5a/b, Notch, and NF-kB JAK,
RAS, PI3K, P38 MAPK, RAS homologue, ARHGEF families,
and WNT3 are associated with cell death, apoptosis, cell survival,
proliferation, and migration. RNAase has binding activity and
regulates transcription; CDKN1A regulates cell cycle. It is likely
that secondary resistance to DAC is associated with those
downstream pathways.
Cytogenetic progression
We analyzed cytogenetic data of MDS patients with primary
and secondary resistance. For those 32 patients involved in the
study of primary resistance, 9 responders had normal cytogenetics,
4 showed abnormalities including translocation of 11 to 20,
deletion of chromosome 5, 10, 11,16 and 20, trisomy19, 20, and 3
had no data. By contrast, 4 non-responders had normal
cytogenetics, 9 showed abnormalities including 5q 13q, 33,
deletion 7 and 19, trisomy 8, 9, and 21 as well as complex
changes, and 3 had no data (Table 2). Two non-responders who
had poor cytogenetics actually had a low CDA/DCK ratio at 0.25
and 0.53, respectively, suggesting that high CDA/DCK is a risk
factor for resistance to DAC, but low CDA/DCK may not be able
to overcome bad karyotypes. For those patients involved in the
study of secondary resistance, at diagnosis, 15 patients had normal
cytogenetics. Of these, three patients showed cytogenetic progres-
sion at relapse (new abnormalities included trisomy 8, deletion
16q, and complex chromosome changes). 15 patients had
abnormal cytogenetics at diagnosis. Of these, 12 had the same
abnormalities at relapse, and 3 had additional changes at relapse
(deletion of chromosome 7 in 1 patient and complex changes in 2
patients). Thus, 6 out of 30 (20%) of patients had evidence of
cytogenetic progression in secondary resistance (Table 2).
Discussion
The two hypomethylating agents DAC and azacitidine have
received FDA approval for the treatment of MDS. However, it
remains unclear why some patients are resistant to treatment. Our
results show that primary resistance to DAC could be related to a
higher ratio of CDA/DCK in a subset of patients, which means
Figure 2. DAC metabolism gene expression in secondary resistance. mRNA expression of hENT1, hENT2, hCNT3, DCK, CDA, MDR1, DNMT1,
DNMT3a, and DNMT3b were measured by quantitative real-time PCR between 14 MDS patients at diagnosis and after relapse. GAPDH was used as an
internal control. Statistical analysis of the difference of gene expression was performed by paired t test.
doi:10.1371/journal.pone.0023372.g002
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and more inactivated through deamination by CDA in non-
responders. Secondary resistance is likely due alternate progression
pathways as we found less aberrant DNA methylation than at
diagnosis, and there were no significant changes in DAC
metabolism gene expression.
Figure 3. Measurement of gene methylation in MDS patients with secondary resistance. A. Pyrosequencing of gene methylation. We
measured methylation of LINE1 and five genes in 20 MDS patients between diagnosis and relapse. Paired t test was used to measure the difference in
methylation levels. B. Difference of methylation between diagnosis and relapse. We calculated the difference in methylation between diagnosis and
relapse and highlight changes above a 10% cut-off.
doi:10.1371/journal.pone.0023372.g003
DAC Resistance in MDS
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complex and remain unresolved. One possibility might result from
insufficient intracellular triphosphate, which has been tested for a
number of drugs such as cytarabine, fludarabine, and 2-CdA in
different trials [6]. However, it remains experimentally very
difficult to test this for DAC because clinical treatment is at low
Figure 4. MCAM analysis of secondary resistance. A. Representative plot of A–M MCAM analysis in one patient. The plot shows Amplitude
(A)=K (log2 R6G), and Magnitude (M)=log2(R/G). The red, black, and blue spots indicate probes hypermethylated, unchanged, and hypomethylated
in MDS patients, respectively. B. Frequency of distribution of SmaI fragments in one patient. Values below 21 indicate hypomethylation at relapse,
while values above 1 indicate hypermethylation. C. Representative plot of A–M MCAM analysis in 4 patients. We averaged A and M in four patients
and performed A–M plot. D. Frequency of distribution of SmaI fragments in 4 patients. We averaged the value of SmaI fragments in four patients and
performed analysis of frequency of distribution. E. Pie diagram of hypermethylated genes at relapse. We calculated the percentage of genes that are
not hypermethylated, hypermethylated in 1 patient, or commonly hypermethylated in 2, 3, or 4 patients at relapse, respectively. Pie diagram was
performed based on the percentage of these genes. F. Pie diagram of hypomethylated genes at relapse. We calculated the percentage of genes that
are not hypomethylated, hypomethylated in 1 patient, or commonly hypomethylated in 2, 3, or 4 patients at relapse, respectively. Pie diagram was
performed based on the percentage of these genes.
doi:10.1371/journal.pone.0023372.g004
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traditional cytotoxic therapies that induce rapid responses in MDS
(mostly after one cycle), DAC has a different pattern of responses,
which are rare after one cycle and improve over time [20,21]. In
humans, DAC has a short half-life (minutes) due to rapid
inactivation in the liver by cytidine deaminase [22,23]. Therefore,
an alternate way to study DAC incorporation/activation is to
measure gene expression related to its metabolic pathways as in
our previous study in-vitro in cancer cell lines [8]. Here, we found
that the CDA/DCK ratio was statistically higher in non-
responders than responders. These data favor a pharmacological
mechanism of primary resistance for a subset of patients. The data
on DCK are particularly relevant clinically given that azacitidine
uses a different enzyme for initial mono-phosphorylation; thus,
some patients with primary resistance to DAC could benefit from
a therapeutic trial with azacitidine. However, multiple mecha-
nisms must be active in different patients as we also found low
CDA/DCK levels in some patients with primary resistance, that
Figure 5. The most prominently affected gene networks generated by Ingenuity Pathway Analysis. A Genes hypomethylated in 2 or
more patients in this network are responsible for lipid metabolism, small molecule biochemistry, and cancer. B Genes hypomethylated in 2 or more
patients in this network are responsible for cell death, cancer, DNA replication, recombination and repair.
doi:10.1371/journal.pone.0023372.g005
Table 2. Cytogenetic progression in MDS patients.
Primary Resistance (Unpaired) Secondary Resistance (Paired)
Time (months) between
diagnosis and relapse
Responders Non-responders Diagnosis Relapse
+19, +20 5q, 13q, 33, 27, +21 Normal +87
25, 210, 211, 216, +19, +20 +8 Normal Del 16 q 10
220, translocation 11 to 20 5q 25 25,272 1
Complex +18, +19 25, 27 +5, 25, 27, +8, 215, 218, 221, 222 12
27, 219 Normal Complex 24
27 5q-, 27, 211, and 220 Complex 14
Complex
Complex
Complex
9 non-responders with primary resistance showing abnormal cytogenetics, 6 patients showing cytogenetic progression from diagnosis to relapse.
doi:10.1371/journal.pone.0023372.t002
DAC Resistance in MDS
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to DAC such as aberrant chromosome changes or defective
induction of apoptosis, and others.
Secondary resistance to hypomethylating agents is emerging as
a serious clinical problem. Survival at relapse after an initial
response is poor. Here, we investigated secondary resistance using
paired diagnosis/relapse samples and find that it is unlikely to be
due to pharmacological mechanisms. We previously found that in-
vitro acquired resistance to DAC in an HL60 cell line was due to
DCK gene mutations [8], which also give rise to resistance to other
NAs in other cell lines [24,25,26,27,28,29]. However, DCK
mutations were not detected in patients after relapse. Similarly,
DCK mutations were rare in clinical resistance to other NAs
[30,31]. Although we found that the CDA/DCK ratio was higher
in primary resistance to DAC, there was no significant difference
in expression of these or other relevant genes between diagnosis
and relapse in this study. The role of gene expression related to
metabolic pathways in secondary resistance to NAs remains
controversial. Some have observed a significant correlation
between these gene expression or protein expression and clinical
outcome to NA with relapsed and/or refractory leukemia.
Conversely, other authors did not find this kind of relationship [6].
Another line of evidence against a pharmacologic mechanism
for secondary resistance is the absence of hypermethylation at
relapse. In fact, we observed that patients had significant
hypomethylation at relapse compared to diagnosis, which cannot
be explained by differential blast counts or other obvious
confounders. Previously, we found that hypermethylation is
accentuated in AML after relapse [12] when patients received
traditional chemotherapy containing cytarabine combinations.
Thus, it is likely that hypomethylation induction by DAC does not
recover in the face of continuing treatment, and that hypomethy-
lation does not prevent patients’ relapse and progression. Indeed,
one cannot exclude the possibility that hypomethylation itself
might eventually lead to progression and resistance to DAC either
through ectopic gene reactivation or by mutagenesis and induction
of chromosomal instability. Moreover, clinical responses to
hypomethylating drugs in-vivo are complex and may involve
differentiation and immune activation components. The bone
marrow microenvironment is also an important factor to modulate
response to chemotherapy [32]. Thus, secondary resistance to
DAC may also arise by complex mechanisms not entirely related
to initial drug disposition.
Cytogenetic analysis showed that MDS patients after relapse
showed evolution in 20% patients with abnormalities such +8,
deletion of 16q, and 27. Cytogenetic evolution in MDS has been
associated with progression to AML, and the new abnormalities
we observed are already recognized as accompanying patients
with poor prognosis, especially those involving loss or rearrange-
ments of chromosome 7 and gain of chromosome 8. There are two
broad critical regions of deletion on the long arm of chromosome 7
at bands 7q22 and 7q34-q36, which may contain important tumor
suppressor genes that could be related to prognosis and resistance
to DAC. This issue should be studied further using high resolution
chromosomal analysis (for example by SNP-arrays) and/or
genome sequencing to identify novel mutations in this setting.
Overall, our data suggest that evolution to a more aggressive clone
that is perhaps less dependent on DNA hypermethylation for
survival may be a common mechanism of secondary resistance to
decitabine.
In conclusion, we found that a high CDA/DCK ratio may be a
marker of primary resistance to DAC in a subset of patients. If
confirmed in other studies, this may help predict response to DAC
treatment based on the value of CDA/DCK, or may steer patients
towards azacitidine therapy, which does not depend on DCK for
activity. By contrast, secondary resistance to DAC is likely
independent of DNA methylation and pharmacologic pathways.
It is more likely that genetic activation of oncogenic survival and
progression pathways contribute to secondary resistance to DAC.
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